Internal Reference Number: FOI_6772
Date Request Received: 09/09/2022 00:00:00
Date Request Replied To: 04/10/2022 00:00:00
This response was sent via: By Email
Request Summary: Intra-vitreal injections or implants
Request Category: Companies
| Question Number 1: How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from May to August 2022: • Aflibercept • Bevacizumab • Brolucizumab • Dexamethasone • Faricimab • Ranibizumab - Lucentis • Ranibizumab - Ongavia | |
| Answer To Question 1: IVTs given between May-Aug 2022 are as follows: Aflibercept - 1700 Bevacizumab - 11 Brolucizumab - 0 Dexamethasone - 11 Faricimab - 0 Ranibizumab (Lucentis) - 51 Ranibizumab (Ongavia) - 0 | |
| Question Number 2: Please see attached question sheet | |
| Answer To Question 2: See attached. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
